Avery. Neonatología Sample

Edited with the trial version of Foxit Advanced PDF Editor To remove this notice, visit: www.foxitsoftware.com/shopping

CAPÍTULO 10 •  Diagnóstico y tratamiento prenatales en la era molecular: indicaciones, procedimientos y técnicas de laboratorio 131

42. National Institute of Child Health and Human Development Amniocentesis Registry. The safety and accuracy of midtrimester amniocentesis . DHEW publication no (NIH) 78–190. Washington, DC: United States Department of Health, Education and Welfare, 1978. 43. Fletcher JC, Evans MI. Maternal bonding in early fetal ultrasound exami- nations. N Engl J Med 1983;308:392. 44. Evans MI, Drugan A, Koppitch FC, et al. Genetic diagnosis in the first trimester: the norm for the 90s. Am J Obstet Gynecol 1989;160:1332. 45. Rhoads GG, Jackson LG, Schlesselman SE, et al. The safety and efficacy of chorionic villus sampling for early prenatal diagnosis of cytogenetic abnormalities. N Engl J Med 1989;320:609. 46. Mujezinovic F, Alfierivic Z. Procedure related complications of amniocen- tesis and chorionic villus sampling: a systematic review. Obstet Gynecol 2007;110:687. 47. Firth HV, Boyd PA, Chamberlain P, et al. Severe limb abnormalities after chorionic villus sampling at 56–66 days’ gestation. Lancet 1991; 337:762. 48. Tabor A. Amniocentesis vs CVS risks . Greece: Fetal Medicine Foundation Kos, 2013. 49. Hanson FW, Happ RL, Tennant FR, et al. Ultrasonography-guided early amniocentesis in singleton pregnancies. Am J Obstet Gynecol 1990;162:1376. 50. Wilson RD. Early amniocentesis: a clinical review. Prenat Diagn 1995;15:1259. 51. NHS Fetal Anomaly Screening Program. Annual report 2011–2012. http:// www.fetalanomaly.screening.nhs.uk 52. Cohn GM, Gould M, Miller RC, et al. The importance of genetic counsel- ing before amniocentesis. J Perinatol 1996;16:352. 53. Evans MI, Hume RF, Johnson MP, et al. Integration of genetics and ultra- sonography in prenatal diagnosis: just looking is not enough. Am J Obstet Gynecol 1996;174:1925. 54. Benaceraff BR, Frigoletto FD. Amniocentesis under continuous ultra- sound guidance: a series of 232 cases. Obstet Gynecol 1983;62:760. 55. Drugan A, Evans MI. Amniocentesis. In: Evans MI, Johnson MP, Yaron Y, et al., eds. Prenatal diagnosis: genetics, reproductive risks, testing, and management . New York: McGraw Hill Publishing Co., 2006:415. 56. Cuckle HS. Epidemiology of aneuploidy. In: Evans MI, Johnson MP, Yaron Y, Drugan A, eds. Prenatal diagnosis: genetics, reproductive risks, test- ing, and management . New York: McGraw Hill Publishing Co., 2006. 57. Yukobowich E, Anteby EY, Cohen SM, et al. Risk of fetal loss in twin pregnancies undergoing second trimester amniocentesis. Obstet Gynecol 2001;98:876. 58. Van der Pol JS, Wolf H, Boer K, et al. Jejunal atresia related to the use of methylene blue in genetic amniocentesis in twins. Br J Obstet Gynaecol 1992;99:141. 59. Drugan A, Sokol RJ, Syner FN, et al. Clinical implications of amniotic fluid AFP in twin pregnancies. J Reprod Med 1989;34:977. 60. Firth HV, Boyd PA, Chamberlain PF, et al. Analysis of limb reduc- tion defects in babies exposed to chorionic villus sampling. Lancet 1994;343(8905):1069. 61. Elejalde BR, deElejalde MM, Acuna JA, et al. Prospective study of amnio- centesis performed between weeks 9 and 16 of gestation: its feasibility, risks, complications and use in early genetic prenatal diagnosis. Am J Med Genet 1990;35:188. 62. Hanson FW, Tennant F, Hune S, et al. Early amniocentesis: outcome, risks and technical problems at less than 12.8 weeks. Am J Obstet Gynecol 1992;166:1707. 63. Johnson JM, Wilson RD, Winsor EJ, et al. The early amniocentesis study: a randomized clinical trial of early amniocentesis versus midtrimester amniocentesis. Fetal Diagn Ther 1996;11:85. 64. Tabor A, Phillip J, Masden M, et al. Randomized controlled trial of genetic amniocentesis in 4606 low risk women. Lancet 1986;1:1287. 65. Odibo AO, Gray DL, Dicke JM, et al. Revisiting the fetal loss rate after second trimester genetic amniocentesis: a single center’s 16 year experi- ence. Obstet Gynecol 2008;111:589. 66. Blessed WB, Lacoste H, Welch RA. Obstetrician-gynecologists performing genetic amniocentesis may be misleading themselves and their patients. Am J Obstet Gynecol 2001;184:1340. 67. Eddleman KA, Malone FD, Sullivan L, et al. Pregnancy loss rates after midtrimester amniocentesis. Obstet Gynecol 2006;108:1067. 68. 69.Wapner RJ, Evans MI, Platt LD. Pregnancy loss rates after amniocen- tesis. Obstet Gynecol 2007;109:780. 69. Nicolaides KH. Pregnancy loss rates after amniocentesis. Obstet Gynecol 2007;109:781. 70. Squier M, Chamberlain P, Zaiwalla Z, et al. Five cases of brain injury fol- lowing amniocentesis in mid-term pregnancy. Dev Med Child Neurol 2000;42(8):554. 71. Rosner M, Pergament E, Andriole S, et al. Detection of genetic abnor- malities using CVS and FISH prior to fetal reduction in sonographically normal appearing fetuses. Prenat Diagn 2013;33:940.

13. National Human Genome Research Institute. Regulation of genetic tests . http://www.genome.gov/10002335 14. Martin JA, Hamilton BE, Osterman MJK, et al. Births: final data for 2012. National Vital Statistics Report: 62 #9 . December 2013. 15. Christianson A, Howson CP, Modell B. Global report on birth defects . White Plains, NY: March of Dimes Birth Defects Foundation, 2006. 16. Evans MI, Hallahan TW, Krantz D, et al. Meta-analysis of first trimes- ter Down syndrome screening studies: free beta hCG significantly out- performs intact hCG in a multi-marker protocol. Am J Obstet Gynecol 2007;196:198. 17. Hassan S, Romero R, Vidyadhari D, et al. Vaginal progesterone reduces the rate of pre-term birth in women with a sonographic short cervix: a mul- ticenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2011;38:18. 18. Shane Michaels H, Nazareth S, Tambini L. Genetic counseling. In: Evans MI, Johnson MP, Yaron Y, Drugan A, eds. Prenatal diagnosis: genetics, reproductive risks, testing, and management . New York: McGraw Hill Publishing Co., 2006:71. 19. Drugan A, Reichler A, Bronshtein M, et al. Abnormal biochemical serum screening versus second trimester ultrasound-detected minor anoma- lies as predictors of aneuploidy in low-risk patients. Fetal Diagn Ther 1996;11(5):301. 20. Drugan A, Johnson MP, Evans MI. Ultrasound screening for fetal chromo- some anomalies. Am J Med Genet 2000;90:98. 21. Benacerraf BR, Nadel A, Bromley B. Identification of second trimester fetuses with autosomal trisomy by use of a sonographic scoring index. Radiology 1994;193:135. 22. Wiwantikit V. Adjusted classification for ultrasound scoring index for antenatal detection of fetal trisomy. Indian J Hum Genet 2012;18:226. 23. Lau TK, Evans MI. Second trimester sonographic soft markers: what can we learn from the experience of first trimester nuchal translucency screening? Ultrasound Obstet Gynecol 2008;32:123. 24. Wright D, Syngelaki A, Bradbury D, et al. First trimester screening for Trisomies 21, 18, and 13 by ultrasound and biochemical testing. Fetal Diagn Ther 2014;35:118. 25. Haddow JE, Palomaki GE, Knight GJ, et al. Screening of maternal serum for fetal Down, 1 syndrome in the first trimester. N Engl J Med 1998;338:955. 26. D’Alton ME. Nuchal translucency quality monitoring: the transition from research to clinical care. Obstet Gynecol 2010;116:806. 27. Evans MI, Cuckle HS. Performance Adjusted Risks (PAR): a method to improve the quality of algorithm performance while allowing all to play. Prenat Diagn 2011;31:797. 28. Souka AP, Von Kaisenberg CS, Hyett JA, et al. Increased nuchal trans- lucency with normal karyotype. Am J Obstet Gynecol 2005;192: 1005. 29. Wapner RJ, Martin CL, Levy B, et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. N Engl J Med 2012;367:2175. 30. Bianchi DW, Simpson JL, Jackson LG, et al. Fetal gender and aneuploidy detection using fetal cells in maternal blood: analysis of NIFTY I Data. Prenat Diagn 2002;22:609. 31. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in mater- nal plasma and serum. Lancet 1997;350:485. 32. Lo YMD. Noninvasive prenatal detection of fetal chromosomal aneuploi- dies by maternal plasma nucleic acid analysis: a review of the current state of the art. BJOG 2009;116:152. 33. Ehrich M, Deciu C, Zwiefelhofer T, et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol 2011;204:205.e1. 34. Sparks AB, Wang ET, Struble CA, et al. Selective analysis of cell free DNA in maternal blood for evaluation of fetal trisomy. Prenat Diagn 2012; 32:3. 35. Bianchi DW, Wilkins-Haug L. Integration of noninvasive DNA testing for aneuploidy into prenatal care: what has happened since the rubber met the road? Clin Chem 2014;60:78. 36. Chitty LS, Bianchi DW. Noninvasive prenatal testing: the paradigm is shifting rapidly. Prenat Diagn 2013;33:511. 37. Galen RS, Gambino SR. Beyond normality: the predictive value and effi- cacy of medical diagnoses . Baltimore, MD: John Wiley and Sons, 1975. 38. Krantz DA, Hallahan TW, Carmichael JB, et al. Utilization of a 1/1000 cut- off in combined screening for Down syndrome in younger women AMA patients provides cost advantages compared with NIPS. Am J Obstet Gynecol 2014;210:S111. 39. Evans MI, Wapner RJ. Invasive prenatal diagnostic procedures 2005. In: Reddy U, Mennuti MT, eds. Semin perinatol. Philadelphia, PA: Elsevier Publishing Company, 2005;29:215. 40. Steel MW, Breg WR. Chromosome analysis of human amniotic fluid cells. Lancet 1966;1:383. 41. Jacobson JB, Barter RH. Intrauterine diagnosis and management of genetic defects. Am J Obstet Gynecol 1967;99:795.

EL FETO COMO PACIENTE

AMPLE